ACYW135 meningococcal polysaccharide vaccine (Beijing Chaoyang District Center for Disease Control and Prevention)

The ACYW135 meningococcal polysaccharide vaccine is a quadrivalent vaccine designed to prevent meningococcal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W-135. This vaccine works by stimulating the body to produce antibodies against these specific bacterial serogroups. ## Description The ACYW135 meningococcal polysaccharide vaccine is an active immunizing agent that contains bacterial capsular polysaccharides derived from Neisseria meningitidis serogroups A, C, Y, and W-135. The vaccine is created through fermentation processes in bioreactors, after which the polysaccharides are purified, stabilized, and lyophilized with preservatives to create the final product[5]. This vaccine is particularly formulated for use in developing countries and aims to protect populations during meningitis outbreaks, especially in high-risk regions like the African meningitis belt[5]. It provides protection against meningococcal diseases including meningococcal meningitis (affecting the brain) and meningococcemia (affecting the blood)[1]. The vaccine works by causing the body to produce its own protection (antibodies) against the targeted bacterial serogroups[1]. However, it's important to note that while effective against serogroups A, C, Y, and W-135, the vaccine does not provide protection against other meningococcal serogroups, such as Group B[1][5]. ## Administration and Dosage The vaccine is typically administered as a single 0.5 mL dose via intramuscular injection[5][8]. For individuals at continued risk of meningococcal disease, booster doses may be recommended according to specific guidelines based on age and risk factors[8][10]. ## Target Population The vaccine is recommended for various groups including: - Individuals with certain diseases or conditions that make them more susceptible to meningococcal infections - People living in, working in, or visiting areas with high risk of meningococcal disease - Certain laboratory personnel and military recruits - Individuals during outbreaks caused by the serogroups contained in the vaccine[1][9] ## Efficacy and Safety The vaccine demonstrates good immunogenicity with high seroconversion rates. It provides protection not only for Y and W135 groups but also strengthens immunity against A and C groups[7]. The incidence of local adverse events is reported to be less than 10 per 100,000[7]. ## Available Formulations There are several formulations of meningococcal vaccines available, including polysaccharide vaccines and newer conjugate vaccines that link the polysaccharides to carrier proteins for enhanced immune response, particularly in younger children[2][9].

Other names

Quadrivalent meningococcal polysaccharide vaccineMPSV4MPSV-4MPSV 4Group A, C, Y and W135 meningococcal polysaccharide vaccine